No annual revenue total was found in Vera Therapeutics, Inc.'s SEC filings.
Vera Therapeutics, Inc. (VERA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$241.7 million. As of Sep 30, 2026 it held $384.0 million in cash and investments and $75.4 million in total debt.
Revenue
—
Net income (TTM)
$-415.31M
-64.8% vs year-ago TTM
Operating cash flow (TTM)
$-375.92M
-78.8% vs year-ago TTM
Free cash flow (TTM)
$-376.05M
-77.8% vs year-ago TTM
EPS (TTM)
$-5.91
-47.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
—
Net cash
$308.61M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VERA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1831828
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$315.5M | -$167.2M | -$102.0M | -$90.9M | -$34.4M |
| Net income | -$299.6M | -$152.1M | -$96.0M | -$89.1M | -$32.6M |
| Diluted EPS | -$4.66 | -$2.75 | -$2.25 | -$3.35 | — |
| Operating cash flow | -$241.1M | -$134.7M | -$92.2M | -$67.6M | -$23.7M |
| Free cash flow | -$241.7M | -$135.7M | -$92.2M | -$67.7M | — |
| Total assets | $734.7M | $655.7M | $175.5M | $131.4M | $83.7M |
| Total liabilities | $130.2M | $78.5M | $73.9M | $54.5M | $14.2M |
| Stockholders' equity | $604.5M | $577.2M | $101.7M | $76.9M | $69.6M |
| Cash and investments | $714.6M | $640.9M | $160.7M | $114.7M | $80.5M |
| Total debt | $77.3M | $54.6M | $53.7M | $31.3M | $13.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 15, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 9, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Other events
|
Jul 7, 2026 | Jul 7, 2026 |
| 8-K |
Current report
Other events
|
Jun 2, 2026 | Jun 2, 2026 |
All 474 Vera Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.